Chicago, Ill. — The American Academy of Pediatrics is advocating for COVID-19 vaccinations for children as young as six months up to 23 months old, marking a significant departure from recent federal recommendations. This updated viewpoint comes amid ongoing debates about vaccine administration protocols across the country.

The academy has released a revised immunization schedule that includes guidance for COVID-19, influenza, and RSV for individuals under 18 years of age. According to the AAP, their recommendations contradict those from the Centers for Disease Control and Prevention’s advisory committee, which has undergone significant changes this year, including the appointment of members with backgrounds in vaccine skepticism.

In May, Health and Human Services Secretary Robert F. Kennedy Jr. halted the CDC’s previous guidance that encouraged vaccinations for all children aged six months and older. The CDC now suggests that decisions about COVID-19 vaccinations for children between six months and 17 years should involve shared discussions with healthcare providers.

The AAP specifically recommends immunization for children under 18 deemed at higher risk for severe illness from COVID-19. This includes those living in long-term care facilities or those who have not previously received a vaccine. Dr. Susan Kressly, president of the AAP, emphasized the importance of providing clear guidance, stating that many families rely on the organization for trustworthy medical advice in a climate of misinformation.

Research indicates that infants and toddlers face a heightened risk of severe complications from COVID-19, highlighting the necessity of vaccination in this age group. However, discrepancies between the AAP’s recommendations and federal guidelines could lead to complications in insurance coverage, often reliant on CDC endorsements. Should there be no endorsement, families may have to bear the financial burden of vaccinations themselves.

The Department of Health and Human Services responded to the AAP’s new guidelines by calling for enhanced conflict-of-interest measures within the academy. They expressed concerns that the AAP’s shift could undermine national immunization policies while prioritizing commercial interests over public health.

Kennedy’s recently altered vaccine panel continues to support annual flu vaccinations but has implemented restrictions on formulations containing thimerosal, a preservative. Meanwhile, the AAP maintains that thimerosal is safe and encourages healthcare providers to use any approved flu vaccine appropriate for their patients.

As the discourse regarding pediatric vaccinations evolves, the AAP’s recommendations may spark further discussions among healthcare providers, families, and policymakers about the safest practices for children during a time when vaccine misinformation is widely circulated.